428 related articles for article (PubMed ID: 34604096)
1. Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy.
Huang F; Santinon F; Flores González RE; Del Rincón SV
Front Oncol; 2021; 11():756001. PubMed ID: 34604096
[TBL] [Abstract][Full Text] [Related]
2. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance.
Hossain SM; Eccles MR
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675114
[TBL] [Abstract][Full Text] [Related]
3. Cellular Reprogramming-A Model for Melanoma Cellular Plasticity.
Granados K; Poelchen J; Novak D; Utikal J
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167306
[TBL] [Abstract][Full Text] [Related]
4. Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance.
Ahmed F; Haass NK
Front Oncol; 2018; 8():173. PubMed ID: 29881716
[TBL] [Abstract][Full Text] [Related]
5. How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance.
Wessely A; Steeb T; Berking C; Heppt MV
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071193
[TBL] [Abstract][Full Text] [Related]
6. The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance.
Diazzi S; Tartare-Deckert S; Deckert M
Oncogenesis; 2023 Feb; 12(1):7. PubMed ID: 36774337
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.
O'Connell MP; Marchbank K; Webster MR; Valiga AA; Kaur A; Vultur A; Li L; Herlyn M; Villanueva J; Liu Q; Yin X; Widura S; Nelson J; Ruiz N; Camilli TC; Indig FE; Flaherty KT; Wargo JA; Frederick DT; Cooper ZA; Nair S; Amaravadi RK; Schuchter LM; Karakousis GC; Xu W; Xu X; Weeraratna AT
Cancer Discov; 2013 Dec; 3(12):1378-93. PubMed ID: 24104062
[TBL] [Abstract][Full Text] [Related]
8. Cancer Cell Phenotype Plasticity as a Driver of Immune Escape in Melanoma.
Benboubker V; Boivin F; Dalle S; Caramel J
Front Immunol; 2022; 13():873116. PubMed ID: 35432344
[TBL] [Abstract][Full Text] [Related]
9. Microenvironment-derived factors driving metastatic plasticity in melanoma.
Kim IS; Heilmann S; Kansler ER; Zhang Y; Zimmer M; Ratnakumar K; Bowman RL; Simon-Vermot T; Fennell M; Garippa R; Lu L; Lee W; Hollmann T; Xavier JB; White RM
Nat Commun; 2017 Feb; 8():14343. PubMed ID: 28181494
[TBL] [Abstract][Full Text] [Related]
10. The Wnts of change: How Wnts regulate phenotype switching in melanoma.
Webster MR; Kugel CH; Weeraratna AT
Biochim Biophys Acta; 2015 Dec; 1856(2):244-51. PubMed ID: 26546268
[TBL] [Abstract][Full Text] [Related]
11. Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma.
Falletta P; Sanchez-Del-Campo L; Chauhan J; Effern M; Kenyon A; Kershaw CJ; Siddaway R; Lisle R; Freter R; Daniels MJ; Lu X; Tüting T; Middleton M; Buffa FM; Willis AE; Pavitt G; Ronai ZA; Sauka-Spengler T; Hölzel M; Goding CR
Genes Dev; 2017 Jan; 31(1):18-33. PubMed ID: 28096186
[TBL] [Abstract][Full Text] [Related]
12. New Insights into the Phenotype Switching of Melanoma.
Pagliuca C; Di Leo L; De Zio D
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551603
[TBL] [Abstract][Full Text] [Related]
13. Phenotype plasticity as enabler of melanoma progression and therapy resistance.
Arozarena I; Wellbrock C
Nat Rev Cancer; 2019 Jul; 19(7):377-391. PubMed ID: 31209265
[TBL] [Abstract][Full Text] [Related]
14. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway.
Rathore M; Girard C; Ohanna M; Tichet M; Ben Jouira R; Garcia E; Larbret F; Gesson M; Audebert S; Lacour JP; Montaudié H; Prod'Homme V; Tartare-Deckert S; Deckert M
Oncogene; 2019 Jul; 38(30):5873-5889. PubMed ID: 31253871
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor of DNA Binding 4 (ID4) is highly expressed in human melanoma tissues and may function to restrict normal differentiation of melanoma cells.
Peretz Y; Wu H; Patel S; Bellacosa A; Katz RA
PLoS One; 2015; 10(2):e0116839. PubMed ID: 25642713
[TBL] [Abstract][Full Text] [Related]
16. Dynamical modeling of proliferative-invasive plasticity and IFNγ signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity.
Subhadarshini S; Sahoo S; Debnath S; Somarelli JA; Jolly MK
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37678920
[TBL] [Abstract][Full Text] [Related]
17. Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications.
Massi D; Mihic-Probst D; Schadendorf D; Dummer R; Mandalà M
Cancer Treat Rev; 2020 Aug; 88():102060. PubMed ID: 32619863
[TBL] [Abstract][Full Text] [Related]
18. Melanoma: Molecular genetics, metastasis, targeted therapies, immunotherapies, and therapeutic resistance.
Wagstaff W; Mwamba RN; Grullon K; Armstrong M; Zhao P; Hendren-Santiago B; Qin KH; Li AJ; Hu DA; Youssef A; Reid RR; Luu HH; Shen L; He TC; Haydon RC
Genes Dis; 2022 Nov; 9(6):1608-1623. PubMed ID: 36157497
[TBL] [Abstract][Full Text] [Related]
19. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.
Capparelli C; Purwin TJ; Glasheen M; Caksa S; Tiago M; Wilski N; Pomante D; Rosenbaum S; Nguyen MQ; Cai W; Franco-Barraza J; Zheng R; Kumar G; Chervoneva I; Shimada A; Rebecca VW; Snook AE; Hookim K; Xu X; Cukierman E; Herlyn M; Aplin AE
Nat Commun; 2022 Mar; 13(1):1381. PubMed ID: 35296667
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cells versus phenotype-switching in melanoma.
Hoek KS; Goding CR
Pigment Cell Melanoma Res; 2010 Dec; 23(6):746-59. PubMed ID: 20726948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
